Industry
-
US Administration releases GLOBE framework
- Fri Oct 2
The Final Rule positions GLOBE as a narrower, more targeted mechanism than originally proposed but still embeds international reference pricing into US federal regulation.
Read more -
ANZ pharma’s reputation slips again
- Wed Sep 30
Despite a slight uptick last year, ANZ pharma’s reputation now hovers just above neutral, according to patient organisations, access and integrity pulling it down.
Read more -
Horizon scanning moves forward; HTA reform left behind
- Wed Sep 30
Inaugural Health Innovation Observatory symposium shows horizon scanning progress as patients express concerns about HTA’s ability to deliver access.
Read more -
Guild, PSA unite against ‘Big Pharma’ dispensing model
- Mon Sep 28
Describing Lilly’s new dispensing tender as a ‘Big Pharma-driven medicine supply model’, pharmacy owners and pharmacists are fighting back.
Read more -
‘Pharma’s launch playbook is being rewritten’
- Mon Sep 28
A survey of 175 pharma executives confirms that value, not volume, is driving commercial launch strategies – and Australia is already impacted.
Read more -
China-US tensions close in on Australia
- Mon Sep 28
As China looks to dominate innovative R&D, Australia must decide where it sits in the New World Order, and what it will pay to make that happen.
Read more -
MA Board candidates make their pitch
- Mon Sep 21
EXCLUSIVE: Nomination statements for all three candidates contesting two director vacancies on the Medicines Australia Board – published in full.
Read more -
How MFN hands MA exactly what it needs
- Mon Sep 21
Medicines Australia enters negotiations with more leverage than at any point in history, reshaping the stakes for government and the GBMA.
Read more








